CNTA insider transaction filings
Centessa Pharmaceuticals plc — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-24. Screen CNTA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | HUSSAIN IQBAL J — Chief Legal Officer | Disposition to issuer (D): 117,645 · Disposition to issuer (D): 5,500 · Disposition to issuer (D): 221,559 (derivative) · Disposition to issuer (D): 166,779 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 160,000 (derivative) · +4 more | EDGAR |
| 2026-06-24 | 4 | Bush Tia L — Chief Technology & Quality Ofc | Disposition to issuer (D): 147,954 · Disposition to issuer (D): 360,338 (derivative) · Disposition to issuer (D): 140,000 (derivative) · Disposition to issuer (D): 27,187 (derivative) · Disposition to issuer (D): 145,208 (derivative) · Disposition to issuer (D): 125,000 (derivative) · +1 more | EDGAR |
| 2026-06-24 | 4 | Deferiere Raphael — Chief Accounting Officer | Disposition to issuer (D): 11,000 · Disposition to issuer (D): 165,000 (derivative) · Disposition to issuer (D): 42,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Accardi Mario Alberto — Chief Executive Officer, Director | Disposition to issuer (D): 243,282 · Disposition to issuer (D): 6,250 (derivative) · Disposition to issuer (D): 16,875 (derivative) · Disposition to issuer (D): 15,300 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 225,000 (derivative) · +1 more | EDGAR |
| 2026-06-24 | 4 | GOYAL ARJUN — Director | Disposition to issuer (D): 462,585 · Disposition to issuer (D): 64,570 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Stuckley Carol — Director | Disposition to issuer (D): 208,474 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Hukkelhoven Mathias — Director | Disposition to issuer (D): 96,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Anderson Karen M. — Chief People Officer | Disposition to issuer (D): 62,085 · Disposition to issuer (D): 75,000 (derivative) · Disposition to issuer (D): 28,336 (derivative) · Disposition to issuer (D): 83,924 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 117,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Medicxi Ventures Management (Jersey) Ltd — 10% owner Medicxi Ventures I LP — 10% owner Medicxi Co-Invest I LP — 10% owner Medicxi Ventures I GP Ltd — 10% owner Medicxi Growth I LP — 10% owner Medicxi Growth Co-Invest I LP — 10% owner Medicxi Growth I GP Ltd — 10% owner Medicxi Secondary I LP — 10% owner Medicxi Secondary Co-Invest I LP — 10% owner Medicxi Secondary I GP Ltd. — 10% owner | Sale (S): 4,398,519 · Sale (S): 55,677 · Sale (S): 3,936,970 · Sale (S): 93,526 · Sale (S): 11,197,303 · Sale (S): 281,162 | EDGAR |
| 2026-06-24 | 4 | Kulkarni Samarth — Director | Disposition to issuer (D): 208,474 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Kanes Stephen — Chief Medical Officer | Disposition to issuer (D): 120,000 · Disposition to issuer (D): 500,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | De Rubertis Francesco — Director | Disposition to issuer (D): 4,398,519 · Disposition to issuer (D): 55,677 · Disposition to issuer (D): 3,936,970 · Disposition to issuer (D): 93,526 · Disposition to issuer (D): 11,197,303 · Disposition to issuer (D): 281,162 | EDGAR |
| 2026-06-24 | 4 | INDEX VENTURES LIFE VI (JERSEY) L.P. — 10% owner Yucca (Jersey) SLP — 10% owner Index Venture Life Associates VI Ltd — 10% owner | Sale (S): 9,812,368 · Sale (S): 149,421 | EDGAR |
| 2026-06-24 | 4 | Crowley John J — Chief Financial Officer | Disposition to issuer (D): 45,000 · Disposition to issuer (D): 600,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) · Disposition to issuer (D): 181,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Weinhoff Gregory M — Chief Business Officer | Disposition to issuer (D): 65,925 · Disposition to issuer (D): 584,321 (derivative) · Disposition to issuer (D): 230,000 (derivative) · Disposition to issuer (D): 31,002 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 100,000 (derivative) · +2 more | EDGAR |
| 2026-06-24 | 4 | ZBAR BRETT I W — Director | Disposition to issuer (D): 64,570 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2026-06-24 | 4 | Hedley Mary Lynne — Director | Disposition to issuer (D): 208,474 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2026-05-18 | 4 | Accardi Mario Alberto — Chief Executive Officer, Director | Tax withholding (F): 604 @ $39.42 | EDGAR |
| 2026-03-27 | 4 | Anderson Karen M. — Chief People Officer | Option exercise (M): 41,076 @ $8.01 · Sale (S): 41,076 @ $30.12 · Option exercise (M): 41,076 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Weinhoff Gregory M — Chief Business Officer | Option exercise (M): 23,998 @ $3.85 · Sale (S): 23,998 @ $30 · Option exercise (M): 23,998 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Anderson Karen M. — Chief People Officer | Option exercise (M): 64,768 @ $4.01 · Sale (S): 64,768 @ $28.21 · Option exercise (M): 10,043 @ $4.01 · Sale (S): 10,043 @ $28.10 · Option exercise (M): 64,768 (derivative) @ $0 · Option exercise (M): 10,043 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4/A | Anderson Karen M. — Chief People Officer | Option exercise (M): 94,224 @ $4.01 · Option exercise (M): 15,174 @ $3.85 · Sale (S): 107,961 @ $26.15 · Sale (S): 12,068 @ $27.13 · Option exercise (M): 94,224 (derivative) @ $0 · Option exercise (M): 15,174 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Anderson Karen M. — Chief People Officer | Option exercise (M): 109,398 @ $4.01 · Sale (S): 107,961 @ $26.15 · Sale (S): 12,068 @ $27.13 · Option exercise (M): 109,398 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Weinhoff Gregory M — Chief Business Officer | Sale (S): 61,253 @ $26.17 · Sale (S): 11,943 @ $27.16 | EDGAR |
| 2026-02-03 | 4 | Deferiere Raphael — Chief Accounting Officer | Grant/award (A): 11,000 @ $0 · Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | HUSSAIN IQBAL J — Chief Legal Officer | Sale (S): 1,010 @ $25.01 · Tax withholding (F): 7,780 @ $24.57 · Sale (S): 38,951 @ $25.15 · Grant/award (A): 40,000 @ $0 · Grant/award (A): 20,000 @ $0 · Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Accardi Mario Alberto — Chief Executive Officer, Director | Tax withholding (F): 2,915 @ $24.57 · Grant/award (A): 68,000 @ $0 · Grant/award (A): 273,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Bush Tia L — Chief Technology & Quality Ofc | Tax withholding (F): 8,549 @ $24.57 · Grant/award (A): 35,000 @ $0 · Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Anderson Karen M. — Chief People Officer | Tax withholding (F): 10,606 @ $24.57 · Grant/award (A): 29,000 @ $0 · Grant/award (A): 117,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Kanes Stephen — Chief Medical Officer | Grant/award (A): 120,000 @ $0 | EDGAR |
| 2026-02-03 | 4 | Crowley John J — Chief Financial Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 181,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Weinhoff Gregory M — Chief Business Officer | Tax withholding (F): 14,158 @ $24.57 · Grant/award (A): 31,000 @ $0 · Grant/award (A): 123,000 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Accardi Mario Alberto — President, Orexin Program | Sale (S): 7,432 @ $28.70 · Sale (S): 2,568 @ $29.21 | EDGAR |
| 2025-12-08 | 4 | Accardi Mario Alberto — President, Orexin Program | Option exercise (M): 5,000 @ $9.53 · Sale (S): 10,000 @ $30 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | HUSSAIN IQBAL J — General Counsel | Option exercise (M): 6,000 @ $5.84 · Sale (S): 6,000 @ $27.64 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Bush Tia L — Chief Technology & Quality Ofc | Option exercise (M): 40,000 @ $9.42 · Sale (S): 40,000 @ $28 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Bush Tia L — Chief Technology & Quality Ofc | Option exercise (M): 40,000 @ $9.42 · Sale (S): 40,000 @ $26 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | Accardi Mario Alberto — President, Orexin Program | Tax withholding (F): 593 @ $24.90 | EDGAR |
| 2025-10-27 | 4 | Accardi Mario Alberto — President, Orexin Program | Option exercise (M): 5,000 @ $8.01 · Sale (S): 8,000 @ $25 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-10-16 | 4 | HUSSAIN IQBAL J — General Counsel | Option exercise (M): 6,000 @ $5.84 · Sale (S): 6,000 @ $22.41 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | Bush Tia L — Chief Technology & Quality Ofc | Option exercise (M): 35,000 @ $9.42 · Sale (S): 35,000 @ $24 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Accardi Mario Alberto — President, Orexin Program | Sale (S): 7,430 @ $21.33 · Sale (S): 742 @ $22.02 | EDGAR |
| 2025-09-15 | 4 | HUSSAIN IQBAL J — General Counsel | Option exercise (M): 6,000 @ $5.84 · Sale (S): 6,000 @ $21.85 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | Bush Tia L — Chief Technology & Quality Ofc | Option exercise (M): 24,792 @ $8.01 · Sale (S): 24,792 @ $20 · Option exercise (M): 25,000 @ $9.42 · Sale (S): 25,000 @ $22 · Option exercise (M): 24,792 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | HUSSAIN IQBAL J — General Counsel | Option exercise (M): 20,000 @ $5.84 · Sale (S): 20,000 @ $20.01 · Option exercise (M): 20,000 @ $5.84 · Sale (S): 20,000 @ $22 · Option exercise (M): 20,000 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | Accardi Mario Alberto — President, Orexin Program | Option exercise (M): 5,000 @ $8.01 · Sale (S): 7,000 @ $20 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-08-15 | 4 | HUSSAIN IQBAL J — General Counsel | Option exercise (M): 6,000 @ $5.84 · Sale (S): 6,000 @ $17.23 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-08-01 | 4 | Accardi Mario Alberto — President, Orexin Program | Tax withholding (F): 597 @ $17.17 | EDGAR |
| 2025-07-30 | 4 | Accardi Mario Alberto — President, Orexin Program | Sale (S): 8,322 @ $15.23 | EDGAR |
| 2025-07-25 | 4 | Weinhoff Gregory M — Chief Business Officer | Option exercise (M): 10,000 @ $3.85 · Sale (S): 10,000 @ $15.56 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Centessa Pharmaceuticals plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-06-24 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-05-22 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-07 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CNTA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →